Clinical trial · Observational
Pancreatic Cancer Molecular Sub-classification Using Endoscopic Ultrasound Tissue Core Biopsy Samples
Pancreatic Cancer Molecular Sub-classification for Prognostic Stratification and Individualized Therapy Using Endoscopic Ultrasound Tissue Core Biopsy Samples
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluated the feasibility and reliability of PDAC molecular subtyping on tissue core biopsies samples acquired under EUS guidance. Moreover, this study will assess the impact of molecular subtypes assessed on EUS-FNB samples in patients with resectable and unresectable (locally advanced, advanced, and metastatic) PDAC undergoing chemotherapy on treatment response and survival and the utility in monitoring disease response to therapy and early occurrence of disease relapse using the TaqMan RNA assay in serum
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Feasibility of PDAC molecular subtyping on biopsy samples
- timeFrame
- At 6 months
- description
- Number of patients in whom molecular subtyping on biopsy samples is obtained
- measure
- Reliability of PDAC molecular subtyping on biopsy samples
- timeFrame
- At 1 year
- description
- concordance between molecular subtyping on biopsy samples and surgery specimens
Secondary outcomes (2)
- measure
- Progression-free-survival (PFS)
- timeFrame
- From date of enrollment assessed until death or up to 3 years
- description
- To assess the impact of molecular subtypes assessed on EUS-FNB samples PFS defined as the time from the date of trial entry until disease progression or relapse.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients referred to EUS with FNB in the suspect of pancreatic cancer * Availability of biopsies obtained during EUS-FNB * Histological diagnosis of pancreatic ductal adenocarcinoma of any stage * Age \>18 and \<80 years * Willing to be followed up at the Fondazione Policlinico A. Gemelli University Hospital * Able to sign informed consent Exclusion Criteria: * Histological diagnoses other than pancreatic ductal adenocarcinoma * Pregnancy or lactation * Unable to sigh informed consent
References
Publications (0)
Data not yet available